Atezolizumab Significantly Improves OS in Locally Advanced or Metastatic NSCLC

Share this content:
Atezolizumab improved overall survival among patients with locally-advanced or metastatic non-small cell lung cancer.
Atezolizumab improved overall survival among patients with locally-advanced or metastatic non-small cell lung cancer.

In contrast with docetaxel, atezolizumab improved overall survival among patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after platinum-based chemotherapy, according to preliminary results from the phase 3 OAK trial.1

For international, open-label, OAK study, investigators randomly assigned 1225 patients to receive either atezolizumab or docetaxel every 3 weeks until disease progression or unacceptable toxicity.

Full results will be submitted for presentation at an upcoming medical meeting in 2016.

A Biologics License Application for atezolizumab in NSCLC was granted Priority Review and action by the U.S. Food and Drug Administration (FDA) is expected by October 19, 2016.

RELATED: Managing PD-1 Inhibitor-induced Pneumonitis

Atezolizumab is already approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.                             

Reference

  1. Phase III study showed Genentech's cancer immunotherapy Tecentriq (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy [press release]. Genentech website. http://www.gene.com/media/press-releases/14634/2016-08-31/phase-iii-study-showed-genentechs-cancer. Updated August 31, 2016. Accessed September 1, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters